Apollo Therapeutics Reports Positive Phase 2a Results for Camoteskimab in Atopic Dermatitis Apollo Therapeutics, a leading portfolio biopharmaceutical company, announced today positive topline results from its Phase 2a CHAMELEON trial evaluating camoteskimab, an investigational anti-IL-18 monoclonal antibody, in patients with…
Areteia Reports Positive Phase III Results for Oral Dexpramipexole in Eosinophilic Asthma Areteia Therapeutics, Inc. announced today that its Phase III EXHALE-4 clinical trial has met key efficacy and safety endpoints for dexpramipexole, an investigational oral therapy being developed as…
Ionis Pharmaceuticals, Inc. marked a major milestone today, celebrating the 10th anniversary of Surf Away+, its signature adaptive community event. What began as an initiative to provide people with spinal muscular atrophy (SMA) access to adaptive surfing has evolved into…
ISG (Information Services Group), a global AI-focused technology research and advisory firm, has announced the winners of the third annual ISG Women in Digital Awards for the Asia Pacific region. The program, launched in the Americas in 2022 and expanded…
Vertex Scientists Honored with Prestigious Lasker~DeBakey Award for Transformational Advances in Cystic Fibrosis Vertex Pharmaceuticals Incorporated announced today that Dr. Paul Negulescu, Senior Vice President, has been named a recipient of the 2025 Lasker~DeBakey Clinical Medical Research Award. Dr. Negulescu…
Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company pioneering innovative cancer therapeutics, announced today it will host a virtual Key Opinion Leader (KOL) event on Thursday, September 18 at 5:00 p.m. ET / 2:00 p.m. PT. The event will spotlight interim…
Ferring Pharmaceuticals Co., Ltd. announced today that Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) has formally accepted the New Drug Application (NDA) for nadofaragene firadenovec, a novel non-replicating intravesical gene therapy developed for patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle…
Seaport Therapeutics a clinical-stage biopharmaceutical company developing next-generation neuropsychiatric medicines, announced that the first participant has been dosed in its Phase 1 clinical study of GlyphAgo™ (SPT-320 or Glyph Agomelatine). GlyphAgo is a novel “Glyphed” oral prodrug of agomelatine designed…
Merck, known as MSD outside of the United States and Canada, announced significant new findings from its Phase 3 STRIDE-13 clinical trial of CAPVAXIVE® (pneumococcal 21-valent conjugate vaccine). The results, presented at the 6th European Society of Clinical Microbiology and…
Westlake Chemical Partners LP (NYSE: WLKP) (the “Partnership”) today reported net income attributable to the Partnership in the second quarter of 2025 of $14.6 million, or $0.41 per limited partner unit, which was in line with second quarter 2024 net…
A large gathering of 2’215 shareholders followed the invitation to the 62nd Annual General Meeting of EMS-CHEMIE HOLDING AG at Domat/Ems on August 9, 2025. A total of 20’467’468 registered shares were represented, corresponding to 92.9% of all shares entitled to vote. The…
The Surface Treatment global business unit of BASF’s Coatings division, operating under the Chemetall brand, has been selected to supply innovative PET recycling washing solutions for Circular Plastics Company’s new plastic recycling plant in Vung Tau, Vietnam. Chemetall will provide a…